Please Wait...

Klause Engelke

Translation skills

Main profile

Klaus Engelke, PhD.
Director of Special Imaging Techniques

Professor Klaus Engelke received a Ph.D. in Physics from the University of Hamburg, Germany for his pioneering work on µCT using Synchrotron Radiation. Afterwards he joined the Osteoporosis Research Group at UCSF (University of California at San Francisco) to develop advanced radiographic methods for the diagnosis of osteoporosis. At UCSF he also developed the first workstation for vertebral fracture analysis using digitized x-rays. He then joined the newly formed Institute of Medical Physics (IMP) at the University of Erlangen, Germany to develop desktop µCT Scanners and advanced image processing methods. Prof. Engelke joined Synarc, now Bioclinica, as a Director of Special Imaging Techniques in 2005. At the University of Erlangen he continues to develop novel in vivo and in vitro image acquisition and analysis techniques for the musculoskeletal field. He has authored more than 100 peer reviewed publications and more than 200 conference contributions. In 2007 he chaired the QCT Task Force that developed the official positions of the International Society of Clinical Densitometry (ISCD) and is member of the committee that developed the German guidelines for the diagnosis and treatment of osteoporosis. In 2017 he was awarded the Dr. John P. Bilezikian Global Leadership Award from the International Society for Clinical Densitometry, which recognizes Klaus for his contributions to the advancement of osteoporosis and bone imaging research. He is also a member of the scientific advisory committee of the International Osteoporosis Foundation and co-chaired the Committee on Bone Densitometry of the International Commission on Radiation Units (ICRU).

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

RT @MdFacep: FDA approvals: Merck's Keytruda wins FDA approval as combination therapy for kidney cancer. BIG! https://t.co/LgCzL1mvaF @Reu…
Bioclinica (7 hours ago)
RT @FDA_Drug_Info: National Prescription Drug Take Back Day is April 27, 2019 from 10:00 AM to 2:00 PM. Learn how to dispose of unused and…
Bioclinica (7 hours ago)
RT @iofbonehealth: #Osteoporosis Int: Spanish National Hip Fracture Registry (RNFC): analysis of its first annual report and international…
Bioclinica (7 hours ago)
RT @HINJ_ORG: New Jersey's biopharmaceutical industry: CIANJ has assembled a panel of industry leaders @Celgene, @Bayer & @PhRMA to discuss…
Bioclinica (7 hours ago)
RT @PhRMA: Last year, the top 15 largest biopharmaceutical companies spent more than $100 billion on R&D, according to @IQVIA_global. More…
Bioclinica (7 hours ago)
RT @SCDM_DataDriven: Registrations for the SCDM 2019 Annual Conference are now open!! #SCDM2019 Register now for the biggest event in the…
Bioclinica (7 hours ago)

Latest Blogs:

Site Payments Solutions
Nonalcoholic steatohepatitis (NASH) development programs
Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box